A Multicenter, Prospective, Observational Study of Jaktinib in Newly Diagnosed Myelofibrosis
NCT07925632, Not yet recruiting, Affiliated Hospital of Nantong University
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Multicenter, Prospective, Observational Study of Jaktinib in Newly Diagnosed Myelofibrosis | ClinicalTrials.gov |
| NCT number | NCT07925632 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Enrollment | 80 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Affiliated Hospital of Nantong University | ClinicalTrials.gov |
| Conditions | Myeloproliferative Neoplasms/Myelofibrosis | ClinicalTrials.gov |
| Interventions | Jaktinib | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | anemia response | 24 weeks | Proportion of participants achieving anemia response at week 24 | ClinicalTrials.gov |
| Secondary | TSS50 | 24 weeks | Proportion of participants with a total symptom score reduction of ≥50% (TSS50) at 24 weeks | ClinicalTrials.gov |
| Secondary | SVR35 | 24 weeks | Proportion of participants with a spleen volume reduction of ≥35% (SVR35) from baseline at week 24 | ClinicalTrials.gov |
| Secondary | Progression-free survival (PFS) | 24 months | The time from the first dose to any of the following events: spleen volume increased by ≥25% from the lowest value recorded; death of any cause. | ClinicalTrials.gov |
| Secondary | Leukemia-free survival (LFS) | 24 months | The time from the first dose to any of the following events: bone marrow smear showed blast cells ≥20%; peripheral blood smear blast cells ≥20% and the absolute blast count ≥1×10E9/L lasts for at least 2 weeks; death of any cause. | ClinicalTrials.gov |
| Secondary | Overall survival (OS) | 24 months | OS was defined as the time from the first dose to death. | ClinicalTrials.gov |
| Secondary | Safety and tolerability | 24 months | The safety and tolerability were evalu- ated from the first dose of jaktinib to 28 days after the last dose. Adverse events (AEs) were graded according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)